US Patent 8,685,980: Claim Scope, Ribociclib Coverage and Patent Landscape
US Patent No. 8,685,980 is a Novartis pyrrolopyrimidine patent covering a broad class of cyclin-dependent kinase 4 and 6, or CDK4/6, inhibitors. Its claims encompass ribociclib and related analogues, including pharmaceutical compositions containing those compounds. The patent issued April 1, 2014, and its ordinary term is generally reported to expire December 21, 2027, subject to any applicable patent-term adjustment.[1]
The patent is commercially important because its structural genus covers the ribociclib scaffold, while claim 9 recites a large set of named compounds that define the principal chemical series. The patent is listed in the FDA Orange Book for Kisqali, the ribociclib product marketed by Novartis.[2]
What does US Patent 8,685,980 protect?
The patent protects substituted pyrrolo[2,3-d]pyrimidine compounds designed to inhibit CDK4 and CDK6. The central structure includes:
- A 7H-pyrrolo[2,3-d]pyrimidine core.
- A cycloalkyl substituent, with cyclopentyl specifically recited in claim 5.
- A 6-carboxamide substituent, broadly defined as CONR5R6.
- An amino-linked heteroaryl substituent at the 2-position.
- A variable nitrogen-containing or oxygen-containing ring system attached through the heteroaryl group.
- Pharmaceutically acceptable salts.
- Pharmaceutical compositions containing the claimed compounds.
The claims do not protect every CDK4/6 inhibitor. They require the accused compound to satisfy the specific structural limitations in the claim, including the pyrrolopyrimidine core, the cycloalkyl group, the carboxamide substituent, and the defined heteroaryl or heterocyclic substituents.
Core structural limitations
Claim 1 is the principal genus claim. Its key limitations can be summarized as follows:
| Claim element |
Scope |
| Core |
Substituted pyrrolo[2,3-d]pyrimidine-type structure |
| X |
CR9, with R9 as hydrogen or halogen |
| R1 |
CONR5R6 |
| R5/R6 |
C1-8 alkyl |
| R2 |
C3-14 cycloalkyl |
| Linker L |
Bond, C1-8 alkylene, C(O), or C(O)NH |
| Heteroaryl or heterocyclic region |
Variable Y and W atoms, including carbon and nitrogen |
| R3 |
Broad alkyl, cycloalkyl, hydroxyalkyl, amino, amide, ester, cyanoalkyl, haloalkyl and related groups |
| Salt form |
Pharmaceutically acceptable salt included |
| Use format |
Composition claim appears separately in claim 7 |
The use of “C1-8 alkyl” for R5 and R6 means claim 1 covers substantially more than the dimethylamide found in ribociclib. Claim 8 narrows this limitation by requiring both R54 and R55 to be methyl.
Does US 8,685,980 cover ribociclib?
Yes. The patent’s claim architecture covers ribociclib, chemically known as 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide.
Ribociclib corresponds to the principal claim variables as follows:
| Ribociclib feature |
Patent claim correspondence |
| 7-cyclopentyl substitution |
R2 as cyclopentyl |
| N,N-dimethyl carboxamide |
R1 as CONR5R6, with both alkyl groups methyl |
| Pyrrolo[2,3-d]pyrimidine core |
Formula I core |
| 2-amino linkage |
L as a bond and the defined amino-heteroaryl arrangement |
| 5-piperazinyl pyridine |
Heteroaryl and heterocyclic substituent definitions |
| Free-base or salt form |
“Compound or pharmaceutically acceptable salt thereof” |
Claim 1 is the principal broad coverage claim. Claims 3, 5, 8 and 10 narrow the genus toward commercially relevant embodiments. Claim 9 is important because it identifies numerous specific compounds in the same chemical series, although the exact listed species must be compared against the marketed ribociclib structure rather than assumed to be identical.
How broad is claim 1?
Claim 1 is materially broader than ribociclib. It covers a chemical genus defined by multiple independently variable positions.
The broadest commercial significance comes from four features:
- R5 and R6 can be different C1-8 alkyl groups, rather than only methyl.
- R2 can be a broad C3-14 cycloalkyl group, rather than only cyclopentyl.
- L can be a direct bond, alkylene, carbonyl or carbamoyl linker.
- The right-hand substituent can contain substituted piperazines, pyrrolidines, bicyclic amines, diazacycles, pyridines, pyridazines and related heterocycles.
The claim therefore reaches a large analogue space around ribociclib. A generic or competing CDK4/6 inhibitor would face infringement risk if it retained the required pyrrolopyrimidine architecture and fell within the listed substituent definitions.
The breadth also creates validity pressure. Potential attack points include:
- Written-description support for the full Markush genus.
- Enablement across the full range of substituent combinations.
- Indefiniteness caused by complex nested definitions.
- Whether particular claimed ring systems are sufficiently identified by the formula drawings and variable definitions.
- Obviousness over earlier kinase-inhibitor and pyrrolopyrimidine disclosures.
- Lack of inventiveness for close analogues with predictable heterocyclic substitutions.
The named compounds in claim 9 provide stronger written-description support for at least the expressly disclosed species. The broader claim 1 is more valuable commercially but more exposed to genus-based validity attacks.
Which claims are strongest against a ribociclib generic?
For a ribociclib generic, the strongest infringement positions are likely claims 1, 7, 8 and the applicable species claims in claim 9.
Claim 1
Claim 1 provides the broadest structural coverage. It can capture ribociclib even where the generic product is supplied as a different pharmaceutically acceptable salt, assuming the salt remains within the claim.
Claim 7
Claim 7 covers a pharmaceutical composition containing a claim 1 compound and a pharmaceutically acceptable carrier. This claim is relevant to a finished dosage form, but it generally requires proof that the marketed composition contains a compound within claim 1.
Claim 8
Claim 8 narrows the structure by specifying the dimethylcarboxamide and selected ring variables. It is narrower than claim 1 but potentially more defensible because its limitations more closely track ribociclib.
Claim 9
Claim 9 recites numerous named chemical entities. Species claims can be valuable in litigation because they reduce claim-construction disputes over broad Markush language. The commercial significance depends on whether the exact ribociclib structure is among the listed species or is covered through the generic claims.
Claims 10 to 15
These claims narrow substituent choices and ring arrangements. Claims 10, 11, 13, 14 and 15 may provide fallback positions if the broadest genus is challenged. Their value depends on whether the accused molecule satisfies each specified limitation.
What formulations are protected?
US 8,685,980 is primarily a composition-of-matter patent. Claim 7 is the express formulation-related claim, but it is broad and does not require a particular tablet, capsule, excipient, release profile or manufacturing process.
The patent does not, based on the supplied claims, specifically require:
- A tablet.
- A particular dosage strength.
- A sustained-release formulation.
- A specific excipient.
- A particular crystalline polymorph.
- A specific salt or hydrate.
- A defined dissolution profile.
- A manufacturing process.
This distinction matters. A generic product could avoid a separate formulation patent while still infringing the composition claims if its active ingredient falls within the claimed compound genus. Conversely, a formulation-specific patent could remain relevant after the composition patent expires.
What is the Orange Book status of US 8,685,980?
US 8,685,980 is listed in the FDA Orange Book in connection with Kisqali, ribociclib tablets. The listed product is approved for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, and in specified early breast-cancer settings under the applicable label.[2][3]
The Orange Book listing gives the patent commercial significance against an ANDA applicant. A generic applicant seeking approval before the listed patent’s expiration would generally need to address the patent through one of the statutory certification pathways, including a Paragraph IV certification if it seeks approval before expiration and asserts that the patent is invalid, unenforceable or not infringed.[4]
The listing does not itself establish that the patent is valid or infringed. It establishes that FDA has received a patent declaration or listing for the approved drug.
When does US 8,685,980 lose exclusivity?
The reported ordinary expiration date is December 21, 2027.[1] The practical exclusivity timeline is:
| Event |
Date or period |
| Earliest reported priority |
December 21, 2007 |
| US grant |
April 1, 2014 |
| FDA approval of Kisqali |
March 13, 2017 |
| Five-year new chemical entity exclusivity |
Generally expired in 2022 |
| FDA pediatric extension |
No extension should be assumed without confirmation in the current FDA record |
| Reported patent expiration |
December 21, 2027 |
| Earliest ordinary generic launch opportunity |
After resolution of patent and regulatory barriers, generally after patent expiration |
Patent expiration does not guarantee immediate generic entry. An ANDA applicant may obtain approval before expiration if it prevails in Paragraph IV litigation, reaches a settlement allowing earlier entry, or establishes noninfringement.
Which companies are challenging the patent?
The supplied record does not identify a specific Paragraph IV notice, ANDA applicant, district-court complaint or settlement directed to US 8,685,980. No company should be characterized as a confirmed challenger solely because it markets another CDK4/6 inhibitor or has filed a ribociclib-related regulatory application.
Potential generic competition would most likely come from companies with established oncology ANDA capabilities, but a definitive challenger list requires a current FDA Orange Book review, Paragraph IV notice records and PACER or district-court docket analysis.
What patent litigation affects Kisqali?
The patent creates a conventional Orange Book litigation risk for any ribociclib ANDA filed with a Paragraph IV certification. The principal litigation questions would be:
- Whether the proposed ribociclib active ingredient falls within claim 1 or a narrower claim.
- Whether the proposed salt is a pharmaceutically acceptable salt covered by the claims.
- Whether the ANDA product infringes claim 7 as a pharmaceutical composition.
- Whether the patent is invalid for obviousness, written-description failure, enablement failure or indefiniteness.
- Whether any later Novartis patents separately cover polymorphs, salts, formulations, dosing regimens or manufacturing methods.
A 30-month stay may apply if the patent holder timely files an infringement action after receiving a Paragraph IV notice.[4] The stay mechanism applies to the ANDA approval process, not to the patent’s substantive validity.
How does this patent compare with other CDK4/6 patent estates?
| Product |
Active ingredient |
Principal sponsor |
Core patent risk |
| Kisqali |
Ribociclib |
Novartis |
Pyrrolopyrimidine composition claims, later formulation and method claims |
| Ibrance |
Palbociclib |
Pfizer |
Distinct pyridopyrimidinone composition and formulation estate |
| Verzenio |
Abemaciclib |
Eli Lilly |
Distinct benzimidazole/pyrimidinyl composition, formulation and method claims |
US 8,685,980 is not a platform patent covering all CDK4/6 inhibitors. Its risk is molecule-specific. Palbociclib and abemaciclib do not ordinarily fall within the ribociclib pyrrolopyrimidine genus because their core structures and substituent arrangements differ.
The patent’s competitive strength is highest against ribociclib copies and close analogues, not against chemically unrelated CDK4/6 inhibitors.
What manufacturing and IP barriers remain after expiration?
The composition patent is the principal barrier through December 2027. Separate barriers may include:
- Process patents covering preparation of ribociclib or intermediates.
- Salt, polymorph or crystalline-form patents.
- Formulation patents.
- Method-of-treatment patents.
- Regulatory exclusivity applicable to a particular supplemental indication.
- Trade secrets involving impurity control, crystallization and scale-up.
- Analytical methods and specifications used for commercial release.
A generic manufacturer could potentially avoid a process patent through an alternative synthesis, but it cannot avoid a composition claim merely by using a different manufacturing route if the final molecule remains within the claim.
How strong is the patent estate for ribociclib?
US 8,685,980 is a strong foundational patent for ribociclib because it combines broad genus coverage with narrower structural fallbacks and a composition claim. Its limitations are also significant:
- The patent expires before the full commercial life of a modern oncology product would otherwise end.
- The complex Markush language creates claim-construction and validity issues.
- The patent does not, from the supplied claims, provide detailed protection for a specific dosage form or release technology.
- A successful Paragraph IV challenge could remove the principal composition barrier before December 2027.
- Later patents, rather than this patent alone, may determine the actual generic-entry date.
Key Takeaways
- US 8,685,980 is a Novartis composition-of-matter patent for pyrrolopyrimidine CDK4/6 inhibitors.
- Its claims cover ribociclib and a broad family of related analogues.
- Claim 1 is the broad genus claim; claims 8 through 15 provide narrower fallback positions.
- Claim 7 covers pharmaceutical compositions containing a claimed compound.
- Claim 9 contains numerous expressly named compounds from the ribociclib chemical series.
- The reported patent expiration date is December 21, 2027.
- The patent is listed in the FDA Orange Book for Kisqali.
- A Paragraph IV challenger would likely contest infringement, obviousness, written description, enablement or indefiniteness.
- The patent does not itself establish protection for a specific polymorph, formulation, dosage regimen or manufacturing process.
- Palbociclib and abemaciclib are competitive CDK4/6 products but are structurally distinct and are not ordinarily covered by this patent.
FAQs
Does US 8,685,980 cover ribociclib succinate?
The claims cover ribociclib and pharmaceutically acceptable salts. Whether a particular ribociclib salt is covered depends on whether it satisfies the claimed compound structure and the legal meaning of pharmaceutically acceptable salt in the claim and specification.
Can a generic launch ribociclib before December 2027?
Yes, but only if the generic obtains approval through a path that removes or avoids the patent barrier, such as prevailing in Paragraph IV litigation, reaching a settlement permitting earlier entry, or demonstrating that the patent does not block the proposed product.
Is US 8,685,980 a method-of-use patent?
No. The supplied claims are directed primarily to compounds and a pharmaceutical composition. They do not expressly claim treatment of breast cancer, CDK4/6 inhibition or a dosing regimen.
Does the patent protect the Kisqali tablet formulation?
Claim 7 covers a pharmaceutical composition containing a claimed compound and a pharmaceutically acceptable carrier. It does not, on the supplied language, require the specific Kisqali tablet formulation, excipient combination or manufacturing process.
Can palbociclib infringe US 8,685,980?
Palbociclib is structurally different from ribociclib. It would not ordinarily be expected to fall within the pyrrolopyrimidine genus claimed in US 8,685,980, although a definitive infringement analysis would require a claim-by-claim structural comparison.
References
- United States Patent and Trademark Office. (2014). U.S. Patent No. 8,685,980, pyrrolopyrimidine compounds as CDK4/6 inhibitors.
- U.S. Food and Drug Administration. (2025). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Kisqali (ribociclib) prescribing information. Novartis Pharmaceuticals Corporation.
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j), including Paragraph IV certification and 30-month stay provisions.
